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Abstract
Aim: This multi-centre, prospective, controlled trial was designed to examine the
biological response of the matrix metalloproteinase(MMP) inhibitor subantimicrobial
dose doxycycline (SDD) combined with access flap surgery on periodontal wound
repair in patients with chronic severe periodontitis.
Material and Methods: Seventy subjects were enrolled into a 12-month,
randomized, placebo-controlled, double-masked trial to evaluate disease response to 6
months therapy and ‘‘wash-out’’ of either placebo1surgery or SDD (20 mg
b.i.d.)1surgery. Primary outcome measure included clinical attachment levels (CAL)
and secondary outcomes included probing depth (PD), bleeding on probing (BOP), as
well as gingival crevicular fluid bone marker assessment [collagen telopeptides
(ICTP)]. These measurements were taken at baseline through 12 months post-surgery
and drug administration.
Results: Patients treated with SDD and surgery demonstrated stronger reductions in
PD in surgically-treated sites of X7 mm as well as gains in CAL (po0.004).
Furthermore, SDD1surgery resulted in short-term reductions in ICTP levels compared
with placebo. Rebounds in ICTP levels and clinical parameters occurred when SDD
was withdrawn.
Conclusions: The results from this multi-centre study suggests that SDD in
combination with surgery improves the short-term response of periodontal therapy by
reducing PD, increasing CAL gain and inhibiting early stage bone resorption.
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It is generally accepted that, although
periodontal disease is initiated by the
subgingival microflora, inflammatory
mediators released by host cells within
the gingival tissues are major factors
responsible for the destruction of the
supporting periodontal tissues (Kornman
2008). Microbial virulence factors trig-
ger the release of host-derived enzymes
such as proteases (e.g., matrix metallo-
proteinases or MMPs) that can lead to
destruction of tooth-supporting tissues
(Slots & Genco 1984, Socransky &
Haffajee 1991, Gopalsami et al. 1993).
MMPs are a family of endopeptidases
with activity against most extracellular
macromolecules (Pussinen et al. 2007).
Collagenases, a subclass of the MMP
family, are a group of enzymes capable
of disrupting the triple helix of type I
collagen in physiological conditions, the
primary structural component of the
periodontium. A number of physiologi-
cal events [i.e., embryonic development
and tissue remodeling (Shi et al.
2007)] and pathologic conditions such
as arthritis (Murphy & Nagase 2008) and
cancer (Lopez-Otin & Matrisian 2007)
are characterized by heightened MMP
activity. Studies have shown elevated
levels of collagenases and other host-
derived proteinases (e.g., cathepsins,
elastase, tryptases/trypsin like protei-
nases) in inflamed gingiva, gingival cre-
vicular fluid (GCF), and saliva of
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humans with periodontal disease (Golub
et al. 1976, 1990, Sorsa et al. 1988).
Therefore, the determination that perio-
dontal tissue destruction is primarily due
to the host response has created areas of
research directed at altering an indivi-
dual’s reaction to the bacterial challenge.
Hence, new methods of host modulatory
therapy for periodontal disease are being
focused beyond the traditional control of
tooth-associated microbial biofilms.
Tetracyclines (TCNs; including the
semi-synthetic analogues, minocycline
and doxycycline) are capable of inhibit-
ing mammalian collagenase activity
(Golub et al. 1997, 2001). TCN’s inhi-
bitory effect on collagenases appears
to occur through the drug’s ability to
bind to zinc cations as well as calcium
ions in the catalytic domain of the
molecule (Golub et al. 1983, 1987).
Furthermore, administration of low
doses of subantimicrobial dose doxycy-
cline (SDD; a tetracycline analogue)
given 20 mg b.i.d. rather than the 50–
100 mg capsules, typically administered
as commercially available antibiotics,
effectively inhibit collagenase activity
in the gingival tissues as well as in GCF
(Golub et al. 1998) without exerting
direct effects on the subgingival micro-
organisms. Several clinical studies have
demonstrated improvements in gingival
healing when SDD is used in combina-
tion with traditional dental prophylaxis
or SRP (Caton et al. 2000, 2001, Novak
2002, Preshaw et al. 2004). More
recently, a modified-released SDD for-
mulation containing 40 mg doxycycline
once a day demonstrated similar posi-
tive results (Preshaw et al. 2008).
Many of the crucial cellular responses
of early post-surgical wound healing,
such as inflammatory infiltration, angio-
genesis and re-epithelialization, are made
possible through the action of MMPs
(Tarlton et al. 1997). Expression of
MMPs such as collagenases is elevated
in acute wounds, and still greater levels
are found in chronic wounds, indicating
that uncontrolled proteolysis is a charac-
teristic of retarded healing (Tarlton et al.
1997, Neely et al. 2000, Gu et al. 2002).
Several members of the MMP family
function as positive and, at times, nega-
tive regulators of repair processes (Gill &
Parks 2008). MMPs have demonstrated
functions in bone including degradation
of collagen and other components of the
bone matrix, migration and survival of
bone cells, endochondral bone formation
and bone resorption (Varghese 2006).
Abnormal expression of MMPs may
also lead to pathological conditions
affecting bone and cartilage (Giannobile
2008). Our group previously demon-
strated in a single centre, proof-of-con-
cept investigation that the utilization of a
6-month dosing of SDD in combination
with access flap surgery could reduce
GCF levels of collagen telopeptides
(ICTP) and reduce pocket depth in
patients with severe periodontitis (Gapski
et al. 2004, Goodson 2004). However,
given the limited sample, a more
expanded, multi-centre investigation
was warranted to better characterize the
responses to therapy. Therefore, the aim
of this multi-centre study was to evaluate
the effect of a MMP-inhibitor (MMPi) in
the post-surgical would healing in a




A written informed consent was provided
for individuals willing to participate in
this trial that met the inclusion and exclu-
sion criteria outlined in a protocol
approved by Institutional Review Board
of Academic Health Centres at the Uni-
versity of Michigan, Boston University
and the Stony Brook University. Three
calibrated surgeons and three separate
individual clinical examiners were uti-
lized from each Clinical Centre. In order
to minimize the impact of inter-examiner
variability, all clinical measurements were
conducted by the same examiner from
each center for the duration of the study.
Before study commencement, the study
examiner was trained and practiced in
each of the clinical measurements. Dupli-
cate measurements were compared to
ensure a standard deviation of o1.0 mm
for repeated within-subject probing depth
(PD) and clinical attachment level (CAL)
measures. The human clinical trial was
performed in accordance with CONSORT
guidelines (Moher et al. 2001). Seventy
subjects (aged 30–75 years) diagnosed
with chronic severe periodontitis were
enrolled into a double-masked, rando-
mized, placebo-controlled, prospective,
parallel arm multi-center trial during the
period of 1999–2003. Patients were
recruited from November of the year
1999 to July of 2002. These patients
were followed until July of 2003 (Fig.
1). Pertinent inclusion criteria included
patients with at least three teeth in the
same sextant demonstrating both PD and
CAL X5 to 412 mm and bleeding on
probing (BOP) with at least 10 teeth in the
functional dentition. Exclusion criteria
included patients chronically treated (i.e.,
2 weeks or more) with any medication
known to affect periodontal status (i.e.,
antibiotics or NSAIDS); those who
received antibiotics within 90 days of
baseline (BL); patients possessing clini-
cally significant or unstable organic dis-
eases; patients displaying compromised




Fig. 1. Patient flow through study.
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nective tissue disorders or bone metabolic
diseases; patients with conditions necessi-
tating antibiotic prophylaxis; females who
were pregnant (as determined by positive
urine pregnancy test at the pre-screening
visit) or lactating, or female patients who
were of childbearing potential and not
utilizing birth control or abstinence;
patients with documented allergies to
TCNs; heavy cigarette smokers
(X2 packs/day); active infectious dis-
eases, immunocompromised or taking
steroid medications.
Study design
Patients eligible to participate in the
study received full mouth scaling and
root planing within 90 days before BL.
Fourteen days before surgery, subjects
were re-examined (screening visit) and
inclusion/exclusion criteria were re-
viewed. Subjects who still qualified for
the study and required access flap sur-
gery in a minimum of one sextant were
randomized to receive either doxycycline
hyclate 20 mg b.i.d. (Periostats, Galder-
ma Labs, Fort Worth, TX, USA) or
placebo capsules b.i.d. for the treatment
period of 6 months. Full mouth manual
clinical measurements were recorded for
all teeth within 2 weeks of the BL
appointment. Six sites were measured
around each tooth in the mouth (mesio-
buccal, buccal, distobuccal, distolingual,
lingual and mesiolingual) for PD, CAL
and BOP. At the same visit, GCF
samples were collected on teeth assigned
to receive surgery. Examiners were
trained to minimize intra-rater (i.e.,
intra-examiner) variability with respect
to the surgical operation and clinical
measures performed.
Surgical procedures were then per-
formed at BL within 14 days from the
screening visit. Patients returned for
follow-up examinations at months 1, 2,
3, 6, 9 and 12 following BL. Full mouth
manual probing measurements and GCF
ICTP levels were assessed at BL and
months 2, 3, 6, 9 and 12. The subjects
received periodontal maintenance ther-
apy at 3, 6, 9 and 12 months following
randomization and periodontal surgery.
The study design is shown in Table 1.
Surgical procedures
Briefly, following local anesthesia,
treatment sextants (sites having
X5 mm pocket depth) received access
flap surgery, which consisted of submar-
ginal primary incisions and full-
thickness mucoperiosteal flap reflection.
The tooth root surfaces were debrided,
scaled and root planed using hand and
sonic instrumentation. Osseous recon-
touring (osteoplasty) when indicated
was performed for flap adaptation. The
tissues were repositioned with Polyglac-
tin 910 (Vicryl, Ethicon Inc., Somer-
ville, NJ, USA) or silk suture materials.
After surgery, patients received pain
control medication (an acetaminophen-
containing analgesic) when needed and
chemical plaque control (0.12% chlor-
hexidine rinse) for 14 days.
Bone marker (ICTP) analysis
GCF was collected before clinical mea-
surements. Gingival tissue surrounding
the site to be sampled was dried with
gauze, and supragingival plaque was
removed. A sterile methylcellulose strip
(Periopapers: IDE-Interstate, Amity-
ville, NY, USA) was gently placed
into the mesiobuccal aspect of each
tooth sulcus or pocket until slight resis-
tance was felt, and the GCF collected
for 10 s. Following collection, the sam-
ple was kept on ice for transport to the
laboratory and stored at  801C. The
frozen samples were then thawed at
room temperature and proteins were
eluted through five centrifugations at
1500 x g for 5 min with 20ml phos-
phate-buffered saline (pH 7.4) contain-
ing 15 nM aprotinin, 1 mM PMSF and
0.1% of human serum albumin as pre-
viously described (Giannobile et al.
1995). GCF ICTP levels were quantified
using radioimmunoassay (RIA; Dia-
Sorin Inc., Stillwater, MN, USA).
Dispensing of study medication/
assessment of compliance
At the screening visit, qualifying
patients were assigned a code and were
then randomized by a computer soft-
ware program to the drug or placebo
group using block randomization meth-
od. At the BL visit, each patient was
issued a 3-month supply of coded study
medication including one container for
AM and another for PM intake. Three
months following surgery, subjects
returned residual capsules and received
an additional 3-month supply. The resi-
dual capsules were counted and retained
at 3 and 6 months after BL. Patient
compliance (as a percentage) with the
dosing schedule was recorded.
Adverse events
All adverse events were recorded. The
need to capture this information was not
dependent upon whether the adverse
event was associated with the use of the
study medication or not. Adverse events
resulting from concurrent illnesses or
reactions to concurrent medications
were also recorded. Each adverse event
was evaluated for duration, intensity and
relationship with the study medication or
other causes. When the different intensi-
ties occurred more frequently than once a
day, the maximum intensity for the event
was recorded. If the intensity category
changed over a number of days, then
these mini-events or changes were
recorded separately (i.e., having distinct
onset days). The investigator used the
criteria below as guidelines for determin-
ing the relationship of the adverse event
to the study drug: (i) a temporal relation-
ship existed between the event and the
use of the drug; (ii) re-administration of
study medication resulted in reappear-
ance or worsening of the reaction; (iii)
previous experience with the suspected
drug resulted in a similar reaction; and
(iv) the event was not related to any
concomitant disease, pre-existing condi-
tion, other drug therapy or environmental
Table 1. Clinical trial longitudinal measures




Full mouth measurements X X X X X X X
Urine pregnancy test X X
Surgery X
C-telopeptide level X X X X X X
Maintenance therapy X X X X
Dispense medication X X
Drug accountability X X
P-SC, pre-screening; SC, screening; M, month; SRP, scaling and root planing; X = timing of
procedue
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factors. One of the following determina-
tions will then document the relationship
of the adverse event to the study drug: not
related, possible and probable.
Statistical analyses
Based upon data presented in Fig. 1 of
Golub et al. 1997, we have 80% power
for detecting a 30 pg/site difference in
mean ICTP, assuming a standard error
of about 50 pg/site and type I error rate
of 5%, between 35 control patients and
35 SDD patients. For analysis, the pri-
mary outcome measure was considered
CAL and secondary outcomes included
PD, BOP, as well as GCF bone marker
assessment ICTP. Patient group differ-
ences in demographics were compared
with a Wilcoxon’s rank sum test for
continuous measures and a w2 test of
association for categorical measures.
For each time point, site-specific levels
of CAL, PD and BOP were first aver-
aged across each tooth of each subject.
The subject-level means of CAL, PD,
BOP and ICTP were estimated via gen-
eralized estimating equations (GEE)
with an independence working correla-
tion matrix; statistical significance was
based upon GEE robust variance esti-
mates to account for: (1) correlation of
teeth from the same subject, and (2)
temporal correlation of values from the
same tooth. Results presented are based
upon GEE models with effects for treat-
ment, time and their interaction. Adjust-
ment for differences among sites was
also examined, but later excluded due to
lack of statistical significance. Standard
errors presented for each outcome at
each time point are based upon the
robust GEE variance estimates. Statisti-
cal significance was defined as any p-
value o0.05; No adjustment was made
for comparisons among multiple time
points. Subjects with missing data were
included in all analyses to the extent of
the actual data that was collected on
those subjects, i.e., an intent-to-treat
analysis was used, and no missing data
were inputted.
Results
Demographics - BL data
A total of 70 patients entered into the
study; 35 were randomized to the SDD
group and 35 to the placebo group.
Thirty-two out of 35 patients in the
drug group and 33 out of 35 in the
placebo group completed the study for
an overall drop-out rate of 7.1%. At BL,
there were no statistically significant
differences between groups regarding
age and gender (Table 2). Twenty-six
percent of SDD subjects reported cur-
rent use of tobacco and 31% in the
placebo group (Table 2, p 5 0.6). In
addition, no significant differences
were noted between the treatment
groups with respect to BL clinical para-
Table 2. Baseline mean demographics, clinical ICTP characteristics of the subject population
Placebo N 5 35 Drug N 5 35 p-value
Age
Mean (SD) 51 ( 10) 47 ( 9) 0.21n
% Males 63 46 0.15w
Current smokers
N (%) 9 (26) 11 (31) 0.60w
BOP (%)
Mean (SD) 56 ( 22) 61 ( 19) 0.34n
PD (mm)
Mean (SD) 3.7 ( 0.7) 3.9 ( 0.5) 0.19n
CAL (mm)
Mean (SD) 3.7 ( 0.9) 3.7 ( 1.0) 0.95n
ICTP (pg/site)
Mean (SD) 80 ( 76) 87 ( 70) 0.70n
% of sites with PD 45 mm
N (%) 15 (12) 17 (10) 0.22n
nBy Wilcoxon’s rank sum test.
wBy w2 test of association.
N, number; SD, standard deviation, BOP, bleeding on probing; PD, probing depth; CAL, clinical
attachment level; ICTP, collagen telopeptide.
















Fig. 2. Effect of subantimicrobial dose doxycycline (SDD) or placebo in combination with
surgery on clinical parameters and collagen telopeptides (ICTP) for all sites receiving
surgery. The shaded background depicts the time of SDD or placebo administration. The bars
represent per-patient standard errors. p values indicate significant treatment group differences
at a time point as determined by generalized estimating equations (GEE). N 5 70 subjects.
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meters (PD, BOP and CAL), ICTP
levels and percentage of sites with
PD 45 mm (Table 2).
Compliance
The mean overall drug compliance for
the SDD-treated patients was 88.4%
(range 0–114%) while the placebo-trea-
ted individuals displayed 89.2% com-
pliance (range 3–100%). Patients had a
tendency to be slightly more compliant
in the morning than in the evening
(90.8% versus 86.7%, respectively;
p 5 0.003). One patient in the drug
group showed low compliance (18%).
Further, there were no statistical signifi-
cant effects of compliance on any treat-
ment differences.
Treatment outcomes - responses in
clinical parameters and ICTP levels
Pooled surgical sites (All PD strata)
The mean per-patient means in BOP,
PD, CAL and ICTP from BL for all
surgical sites is shown in Fig. 2. As
expected, both placebo and test groups
demonstrated a statistically significant
reduction in PD compared with BL,
however, no differences between groups
was found. Surgical therapy resulted in
mean CAL gains in both groups
(po0.05). In addition, SDD-treated
subjects demonstrated statistically sig-
nificant reduced GCF ICTP levels com-
pared with placebo immediately after
the surgery (2 months, p 5 0.03).
Moderate sites (BL PD 5–6 mm)
Mean per-patient averages in BOP, PD,
CAL and ICTP levels from BL at surgi-
cal sites with a BL PD of 5–6 mm is
shown in Fig. 3. Consistent with results
from pooled PD strata, there were sig-
nificant reductions in PD and gains in
CAL compared with BL for both drug
and control groups. In addition, SDD
group demonstrated a statistically signif-
icant decreased expression of GCF ICTP
levels compared with placebo immedi-
ately after the surgery (2 months,
p 5 0.001). There was a statistically sig-
nificant reduction in percentage of BOP
sites at 3 months between drug and
placebo groups (p 5 0.02). Both SDD
and placebo groups showed comparable
levels in percentage of sites BOP after
the patients discontinued drug therapy
(p40.05).
Deep sites (BL PD X7 mm)
Figure 4 shows the mean per patient
averages in BOP, PD, CAL and ICTP
levels for initially deep probing sites.
Greater reductions in PD were noted in
this PD stratum for both SDD and
placebo groups. The drug therapy
resulted in greater reductions in PD
compared with controls at 3 months
(p 5 0.004). In addition, SDD-treated
patients demonstrated a statistically
significant increase in CAL compared
with placebo during the drug adminis-
tration (3 months, p 5 0.02; 6 months,
p 5 0.005).
Adverse events
The distributions of the adverse events
were correspondingly distributed
between the test and placebo groups.
Overall, 58 patients (28 drug and 28
placebo) reported total of 93 adverse
events during the course of the study
and that could be classified according to
oral and systemic criteria (Table 3).
Overall, adverse events affecting the
oral soft and hard tissues included post-
surgical pain and/or erythema (38.7% of
events), tooth sensitivity (8.6% of
events) and periodontal abscess (6.4%
of events). Excluding pulpitis, tooth
fracture and soft tissue lesions, the other
events appeared to be due to the antici-
pated responses to surgery and was not
attributable to the study medication.
Two patients from the test group devel-
oped soft tissue oral lesions. One patient
developed a soft tissue lesion at 3
months of the trial and it was diagnosed
at 12 months as lichen planus. She
received topical doses of fluocinonide
to manage the area. The other patient
developed oral ulcers 1 week after the
surgery. The patient did not report other


















Fig. 3. Effect of subantimicrobial dose doxycycline (SDD) or placebo in combination with
surgery on clinical parameters and collagen telopeptides (ICTP) levels for initial pockets of
5–6 mm. The shaded background depicts the period of drug or placebo administration. The
bars represent per-patient standard errors. p values indicate significant treatment group
differences at a time point as determined by generalized estimating equations (GEE). N 5 70
subjects.
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episodes during the rest of the trial,
although had a past history of such
lesions. The systemic adverse events
during the study included headaches
(6.4% of events) and common cold
(6.4% of events). Myocardial infarction
occurred in a patient who had not
received the medication. This event
occurred soon before the BL appoint-
ment and therefore, the patient was
exited from the study.
Discussion
This multi-center investigation sought to
evaluate the potential additive effect of
SDD to modulate wound repair in con-
junction with periodontal surgery. The
goal was to explore the clinical and
biochemical impact of this drug on the
modulation of wound healing post-sur-
gically. Following mechanical therapy
in the form of scaling and root planing,
patients then received access flap sur-
gery and were randomized to SDD or
placebo groups for 6 months of drug
therapy, followed by a 6-month ‘‘wash-
out’’. The patients exhibited moderate
to severe horizontal bone loss, not indi-
cated for conventional regenerative
therapy. Therefore, patients included in
this trial exhibited bone loss patterns
with limited treatment options. When
SDD was administered in combination
with surgery, greater wound repair was
found in the form of PD reduction and
increase in CAL compared with placebo
(Figs 2–4). SDD therapy may promote
more rapid wound maturation by inhi-
biting collagen disruption and promot-
ing collagen neogenesis. Therefore,
differences in timing, quality and quan-
tity of wound consolidation in the per-
iodontium might have promoted an
additive therapeutic effect in the SDD
patients. Further statistical analysis also
revealed that there were limited centre
effects (data not shown). In fact, the
significant differences indicated in the
plots remained significant (with nearly
identical p-values) after adjusting for
clinical site confounders.
In this study, the inhibition of MMP
via SDD resulted in a decrease in the
bone resorption biomarker, ICTP, levels
at 2 months after the surgical therapy
while placebo demonstrated increases in
ICTP levels over the same observation
period. ICTP reflects the amount of
organic matrix being disrupted in alveo-
lar bone (specifically collagen type I)
following osteoclastic bone resorption.
ICTP has been utilized as a bone resorp-
tion marker in several systemic disease
states including osteoarthritis (Berger et
al. 2005), rheumathoid arthritis (Chopin
et al. 2008), osteochondrosis (Vervuert
et al. 2007), primary tumours and metas-
tasis (Kong et al. 2007) and many other
skeletal conditions. It has been shown
by histological human data that osteo-
clastic activity peaks immediately after
the bone is exposed by surgical opera-
tions (Wilderman et al. 1970). There-
fore, release of excessive osteoclastic
collagenases (or MMP-13) may have
increased the disruption of collagen
type I in bone and consequently
increased ICTP release in the placebo.
SDD-treated subjects displayed lower
levels of wound fluid ICTP after surgery
compared with BL, suggesting a ‘‘bone-
sparing effect’’ of the drug. In fact,
some studies have demonstrated that
chemically modified TCNs not only
inhibit bone resorption through their
ability to inhibit MMPs but also
by inducing apoptosis of osteoclasts,
by inhibiting osteoclastic resorption
and by inhibiting osteoclastogenesis
(Holmes et al. 2004). Hence, our find-
ings have demonstrated that utilization
of an MMPi may have a direct impact
on post-surgical bone turnover. Although
these findings are limited to this subset of
patients from our trial, these results
should encourage further exploration of
the impact of host modulatory agents on
bone maintenance.
The MMPs are a family of 23 endo-
peptidases in humans (Clark et al. 2008)
that were originally described as cleav-
ing extracellular matrix macromole-
cules, but it is now clear that they have
much wider functionality (Clark et al.
2008). Control over MMP and/or tissue
inhibitor of metalloproteinases activity
in vivo occurs at different levels and
involves factors such as regulation of
gene expression, activation of zymogens
and inhibition of active enzymes by
specific inhibitors. Nearly 60 different
MMPis have been pursued as clinical
candidates to date (Dorman et al. 2007).

















p = 0.02 p = 0.005
Fig. 4. Effect of low dose doxycycline (SDD) or placebo in combination with surgery on
clinical parameters and collagen telopeptides (ICTP) for initial pocket of X7 mm. The
shaded background depicts the time of drug or placebo administration. The bars represent
per-patient standard errors. p values indicate significant treatment group differences at a time
point as determined by generalized estimating equations (GEE). N 5 70 subjects.
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Targeted indications included rheuma-
toid arthritis, cardiovascular diseases,
periodontal disease and many others
(Giannobile 2008). MMPs have been
considered prognostic factors in various
types of cancer as well as promising
targets for cancer therapy (Mannello
2006). Although numerous drug thera-
pies to inhibit MMPs have been
explored, only one agent SDD is cur-
rently approved for clinical use (Corbitt
et al. 2007). This multi-centre rando-
mized-clinical trial has demonstrated
positive effect of an MMPi, SDD on
post-surgical wound healing in patients
with severe chronic periodontitis, at soft
and hard tissue level. These results
should encourage future basic and trans-
lational research in order to find even
more effective MMPis. The next gen-
erations of MMPi should have specifi-
city, gained from an understanding not
only of the catalytic domain structures
but the role of extracatalytic motifs in
substrate binding (Murphy & Nagase
2008). In fact, innovative approaches
for the design of selective MMP inhibi-
tors are currently being performed
including the integration of medicinal
chemistry structure-based properties
and design features (Dorman et al.
2007). This approach, which includes
privileged structures, molecular frame-
works, bioisosteric and bioanalogous/
isofunctional modifications may lead to
more highly selective MMPi in the
future.
Conclusions
Six-month administration of MMPi,
SDD, displayed an enhanced perio-
dontal post-surgical wound healing
compared with placebo controls. Early,
transient reductions in the bone resorp-
tion marker ICTP were also found in
patients while on the drug, suggesting
the potential of SDD to act as a bone-
sparing agent.
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Scientific rationale for the study: The
determination that periodontal tissue
destruction is primarily due to the
host response has created areas of
research directed at altering an indi-
vidual’s reaction to the bacterial
challenge. Hence, new methods of
host modulatory therapy for perio-
dontal disease are being focused
beyond the traditional control of
tooth-associated microbial biofilms.
Principal findings: This manuscript
demonstrates that the utilization of a
6-month dosing of a MMP inhibitor,
SDD in combination with access flap
surgery enhances periodontal post-
surgical wound healing compared
with placebo. Furthermore, transient
reductions in the bone resorption
marker were also found in patients
while on the drug, suggesting the
potential of SDD to act as a bone-
sparing agent.
Practical implications: These results
support and encourage further
exploration of the impact of host
modulatory agents for periodontal
repair and bone maintenance.
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